[go: up one dir, main page]

EA201391568A1 - Новые производные имидазола, подходящие для лечения артрита - Google Patents

Новые производные имидазола, подходящие для лечения артрита

Info

Publication number
EA201391568A1
EA201391568A1 EA201391568A EA201391568A EA201391568A1 EA 201391568 A1 EA201391568 A1 EA 201391568A1 EA 201391568 A EA201391568 A EA 201391568A EA 201391568 A EA201391568 A EA 201391568A EA 201391568 A1 EA201391568 A1 EA 201391568A1
Authority
EA
Eurasian Patent Office
Prior art keywords
arthritis
treatment
derivatives suitable
imidazol derivatives
new
Prior art date
Application number
EA201391568A
Other languages
English (en)
Inventor
Норман Эрл Хьюэс
Тимоти Эндрю Вудс
Брайан Херст Норман
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201391568A1 publication Critical patent/EA201391568A1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88Nitrogen atoms, e.g. allantoin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

В изобретении предложены соединения приведенной ниже формулыгде А, X и R1-R6 такие, как описано в настоящей заявке, их фармацевтически приемлемые соли и фармацевтическая композиция, содержащая указанное соединение; способы лечения боли, связанной с остеоартритом с применением одного из указанных соединений или их фармацевтически приемлемых солей, а также способы получения указанных соединений.
EA201391568A 2011-05-26 2012-05-10 Новые производные имидазола, подходящие для лечения артрита EA201391568A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161490222P 2011-05-26 2011-05-26
PCT/US2012/037200 WO2012161965A1 (en) 2011-05-26 2012-05-10 Novel imidazole derivatives useful for the treatment of arthritis

Publications (1)

Publication Number Publication Date
EA201391568A1 true EA201391568A1 (ru) 2014-04-30

Family

ID=46148987

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201391568A EA201391568A1 (ru) 2011-05-26 2012-05-10 Новые производные имидазола, подходящие для лечения артрита

Country Status (23)

Country Link
US (1) US8648200B2 (ru)
EP (1) EP2714679A1 (ru)
JP (1) JP2014518886A (ru)
KR (1) KR20130143138A (ru)
CN (1) CN103562200A (ru)
AR (1) AR086254A1 (ru)
AU (1) AU2012259234A1 (ru)
BR (1) BR112013029692A2 (ru)
CA (1) CA2836240A1 (ru)
CO (1) CO6811858A2 (ru)
CR (1) CR20130534A (ru)
DO (1) DOP2013000276A (ru)
EA (1) EA201391568A1 (ru)
EC (1) ECSP13013047A (ru)
IL (1) IL229318A0 (ru)
MA (1) MA35128B1 (ru)
MX (1) MX2013013859A (ru)
PH (1) PH12013502435A1 (ru)
SG (1) SG195020A1 (ru)
TN (1) TN2013000434A1 (ru)
TW (1) TW201311658A (ru)
WO (1) WO2012161965A1 (ru)
ZA (1) ZA201308609B (ru)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8871947B2 (en) 2013-02-04 2014-10-28 KingChem LLC Preparation of alkyl 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid ester
CN103467379A (zh) * 2013-08-23 2013-12-25 江苏恒安化工有限公司 3-三氟甲基-1-甲基吡唑-4-甲酸的制备方法
CN103483250B (zh) * 2013-10-08 2015-07-22 南京复兴生物科技有限公司 一种5-氨甲基烟酸的制备方法
CN103601675B (zh) * 2013-10-08 2015-10-28 南京复兴生物科技有限公司 一种5-氨甲基烟酸的制备方法
CN104379551B (zh) 2013-12-09 2017-03-08 金凯有限责任公司 3‑二氟甲基‑1‑甲基‑1h‑吡唑‑4‑羧酸烷基酯及其类似物的制备方法
TWI651310B (zh) * 2014-02-20 2019-02-21 日商日本煙草產業股份有限公司 三化合物及其醫藥用途
JP6566444B2 (ja) 2014-03-19 2019-08-28 カーザ グローバル エルエルシーCurza Global, Llc 2−(アシルアミノ)イミダゾールを含む組成物および方法
CN105636951B (zh) 2014-04-14 2018-05-15 上海恒瑞医药有限公司 酰胺类衍生物及其可药用盐、其制备方法及其在医药上的应用
SG11201800698VA (en) 2015-08-17 2018-03-28 Japan Tobacco Inc Hydroxytriazine compound and medical use thereof
EP3601232B1 (en) 2017-03-31 2022-11-23 Curza Global LLC Compositions and methods comprising substituted 2-aminoimidazoles
CN109293567A (zh) * 2018-11-23 2019-02-01 上海睿腾医药科技有限公司 一种5-溴-2-甲基烟酸乙酯的合成方法
AU2020293584A1 (en) 2019-06-14 2022-01-20 Janssen Pharmaceutica Nv Pyridine carbamates and their use as GluN2B receptor modulators
PH12021553256A1 (en) 2019-06-25 2022-08-08 Gilead Sciences Inc Flt3l-fc fusion proteins and methods of use
PL4045083T3 (pl) 2019-10-18 2024-05-13 Forty Seven, Inc. Terapie skojarzone do leczenia zespołów mielodysplastycznych i ostrej białaczki szpikowej
EP4052040A1 (en) 2019-10-31 2022-09-07 Forty Seven, Inc. Anti-cd47 and anti-cd20 based treatment of blood cancer
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
CN110845426A (zh) * 2019-11-29 2020-02-28 都创(上海)医药科技有限公司 一种2-氯-5-氰基嘧啶化合物制备方法
SI4081305T1 (sl) 2019-12-24 2025-03-31 Carna Biosciences, Inc. Spojine, ki modulirajo diacilglicerol kinazo
CN115087488A (zh) 2020-02-14 2022-09-20 震动疗法股份有限公司 与ccr8结合的抗体和融合蛋白及其用途
BR112022020769A2 (pt) 2020-05-01 2022-12-20 Gilead Sciences Inc Compostos de 2,4-dioxopirimidina de inibição de cd73
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
KR20240023628A (ko) 2021-06-23 2024-02-22 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
US11932634B2 (en) 2021-06-23 2024-03-19 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
CN117396478A (zh) 2021-06-23 2024-01-12 吉利德科学公司 二酰基甘油激酶调节化合物
KR20240023629A (ko) 2021-06-23 2024-02-22 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
US20230183216A1 (en) 2021-10-28 2023-06-15 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
CR20240173A (es) 2021-10-29 2024-06-20 Gilead Sciences Inc Compuestos de cd73
WO2023122615A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
EP4452414A2 (en) 2021-12-22 2024-10-30 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023127883A1 (ja) 2021-12-28 2023-07-06 日本新薬株式会社 インダゾール化合物及び医薬
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Parp7抑制劑
HUE069263T2 (hu) 2022-03-17 2025-02-28 Gilead Sciences Inc Ikarosz cink-ujj család degradálói és azok alkalmazása
US20230355796A1 (en) 2022-03-24 2023-11-09 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
IL316058A (en) 2022-04-21 2024-11-01 Gilead Sciences Inc Compounds modulate KRAS G12D
IL317958A (en) 2022-07-01 2025-02-01 Gilead Sciences Inc CD73 compounds
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
CN120225509A (zh) 2022-12-22 2025-06-27 吉利德科学公司 Prmt5抑制剂及其用途
WO2024215754A1 (en) 2023-04-11 2024-10-17 Gilead Sciences, Inc. Kras modulating compounds
WO2024220917A1 (en) 2023-04-21 2024-10-24 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025006720A1 (en) 2023-06-30 2025-01-02 Gilead Sciences, Inc. Kras modulating compounds
WO2025024811A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
US20250066328A1 (en) 2023-07-26 2025-02-27 Gilead Sciences, Inc. Parp7 inhibitors
US20250101042A1 (en) 2023-09-08 2025-03-27 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025054530A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
WO2025096589A1 (en) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005295752A1 (en) * 2004-10-15 2006-04-27 Amgen Inc. Imidazole derivatives as vanilloid receptor ligands
US8084466B2 (en) * 2007-12-18 2011-12-27 Janssen Pharmaceutica Nv Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor
WO2009103778A1 (en) 2008-02-19 2009-08-27 Novasaid Ab Compounds and methods
UY32470A (es) 2009-03-05 2010-10-29 Boehringer Ingelheim Int Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
WO2010127152A2 (en) * 2009-04-29 2010-11-04 Irm Llc Compounds and compositions as microsomal prostaglandin e synthase-1 inhibitors
WO2011048004A1 (en) * 2009-10-23 2011-04-28 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin e2 synthase-1
AR084174A1 (es) * 2010-12-21 2013-04-24 Lilly Co Eli Compuestos de imidazol-2-benzamida utiles para el tratamiento de osteoartritis y una composicion farmaceutica

Also Published As

Publication number Publication date
MX2013013859A (es) 2014-05-28
MA35128B1 (fr) 2014-05-02
CO6811858A2 (es) 2013-12-16
JP2014518886A (ja) 2014-08-07
CA2836240A1 (en) 2012-11-29
EP2714679A1 (en) 2014-04-09
KR20130143138A (ko) 2013-12-30
CR20130534A (es) 2014-03-12
ECSP13013047A (es) 2014-01-31
PH12013502435A1 (en) 2014-01-13
TN2013000434A1 (en) 2015-03-30
ZA201308609B (en) 2015-05-27
DOP2013000276A (es) 2014-03-31
BR112013029692A2 (pt) 2017-01-17
TW201311658A (zh) 2013-03-16
CN103562200A (zh) 2014-02-05
IL229318A0 (en) 2014-01-30
SG195020A1 (en) 2013-12-30
US20120302608A1 (en) 2012-11-29
AR086254A1 (es) 2013-11-27
AU2012259234A1 (en) 2013-11-14
US8648200B2 (en) 2014-02-11
WO2012161965A1 (en) 2012-11-29

Similar Documents

Publication Publication Date Title
EA201391568A1 (ru) Новые производные имидазола, подходящие для лечения артрита
EA201270560A1 (ru) Спиропиперидиновые соединения и их фармацевтическое применение для лечения диабета
CY1119090T1 (el) Δευτεριωμενα παραγωγα ιβακαφτορης
EA201590879A1 (ru) Арилконденсированные и гетероарилконденсированные лактамы
EA201490647A1 (ru) Производные бензотиазол-6-илуксусной кислоты и их применение для лечения вич-инфекции
EA201891103A1 (ru) Композиции для лечения спинальной мышечной атрофии
EA201690094A1 (ru) Ингибиторы syk
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
UA110983C2 (ru) Производная 1,2,3,4-тетрагидрохинолина, пригодная для лечения диабета
EA201290416A1 (ru) Новые спиропиперидиновые соединения
EA201891553A1 (ru) Ингибиторы syk
EA201590693A1 (ru) Ингибиторы gdf-8
EA201490673A1 (ru) Производные пирролопиримидина и пурина
UA111841C2 (uk) Сполуки бензотіазолу та їх фармацевтичне застосування
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
EA201490650A1 (ru) Фармацевтические композиции
EA201290632A1 (ru) Производные бетулина
EA201391000A1 (ru) Индольные соединения или их аналоги, полезные для лечения возрастной макулярной дегенерации (amd)
EA201590975A1 (ru) Ингибиторы prmt5 и их применение
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
EA201101583A1 (ru) Ингибиторы pi3 киназы или mtor
EA201300250A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена
EA201270752A1 (ru) Ингибиторы киназы и способ лечения злокачественной опухоли с их помощью
EA201391029A1 (ru) Производные оксазина и их применение при лечении неврологических нарушений
EA201390626A1 (ru) Производные гидроксамовой кислоты и применение указанных производных в лечении бактериальных инфекций